Marksans Pharma Ltd. - Research Center

---

Results

• Quarterly
• Half yearly
• Annual

Statement

• Balance sheet
• P&L
• Cash flow

More

• Dividend
• Share holding
• Capital structures
• Ratio

Sep ' 23	Sep ' 22	Mar ' 22	Sep ' 21	Sep ' 20

Sales

386.71

329.41

342.22

316.07

293.51

Operating profit

64.06

45.38

54.69

59.03

52.05

Interest

0.49

2.11

1.96

1.83

2.11

Gross profit

112.12

83.74

72.44

79.73

62.95

EPS (Rs)

1.67

1.47

1.16

1.38

1.11

Other income

48.55

40.47

19.71

22.54

13.01

Stock adjustment

-3.65

-3.91

3.40

0.49

0.07

Raw material

185.62

170.25

163.64

164.35

137.29

Power and fuel

-

-

-

-

-

Employee expenses

35.16

26.87

30.50

29.96

25.13

Excise

-

-

-

-

-

Admin and selling expenses

-

-

-

-

-

Research and development expenses

-

-

-

-

-

Expenses capitalised

-

-

-

-

-

Other expenses

105.53

90.82

89.99

62.24

78.97

Provisions made

-

-

-

-

-

Depreciation

13.22

9.05

9.13

8.53

7.01

Taxation

23.42

15.25

15.82

14.70

10.34

Net profit / loss

75.48

59.44

47.48

56.50

45.59

Extra ordinary item

-

-

-

-

-

Prior year adjustments

-

-

-

-

-

Equity capital

45.32

40.42

40.93

40.93

40.93

Equity dividend rate

-

-

-

-

-

Agg.of non-prom. shares (Lacs)

-

-

-

-

-

Agg.of non promotoholding (%)

-

-

-

-

-

OPM (%)

16.56

13.78

15.98

18.68

17.73

GPM (%)

25.76

22.64

20.01

23.55

20.54

NPM (%)

17.34

16.07

13.12

16.69

14.87